MIST News and Press, Milestone Pharmaceuticals Inc. From 03/24/22

Milestone Pharmaceuticals press release (NASDAQ:MIST): Q4 GAAP EPS of -$0.40 misses by $0.04. As of December 31, 2021, cash, cash equivalents, and short-term investments of $114.1 million, compared to $142.3 million as of December 31, 2020, For further details see: Milestone Pharmaceuti...

Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Clinical and Corporate Update Canada NewsWire - RAPID topline data readout expected mid-second half 2022 MONTREAL and CHARLOTTE, N.C., March 24, 2022 ...

Milestone Pharmaceuticals Announces Appointment of David Bharucha, M.D., Ph.D., as Chief Medical Officer Canada NewsWire MONTREAL and CHARLOTTE, N.C., Feb. 16, 2022 /CNW/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focu...

Milestone Pharmaceuticals to Present at the H.C. Wainwright BIOCONNECT Virtual Conference Canada NewsWire MONTREAL and CHARLOTTE, N.C., Jan. 4, 2022 /CNW/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the...

Milestone Pharmaceuticals Announces Presentation of Heart Rate Analysis of NODE-301 Trial of Etripamil in Patients with PSVT Canada NewsWire - Etripamil significantly decreased heart rate during SVT episodes and independent of conversion to SR – - HR cha...

Milestone Pharmaceuticals (NASDAQ:MIST): Q3 GAAP EPS of -$0.34 beats by $0.04. As of September 30, 2021, Milestone had cash, cash equivalents, and short-term investments of $126.4M Press Release For further details see: Milestone Pharmaceuticals EPS beats by $0.04

Milestone Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Clinical and Corporate Update Canada NewsWire MONTREAL and CHARLOTTE, N.C., Nov. 12, 2021 /CNW/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutic...

Milestone Pharmaceuticals to Present at the 2021 Cantor Fitzgerald Virtual Global Healthcare Conference PR Newswire MONTREAL and CHARLOTTE, N.C., Sept. 22, 2021 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical com...

Milestone Pharmaceuticals to Present at the H.C. Wainwright 23rd Annual Global Investment Conference PR Newswire MONTREAL and CHARLOTTE, N.C., Sept. 7, 2021 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company...

Milestone Pharmaceuticals (NASDAQ:MIST): Q2 GAAP EPS of $0.02 beats by $0.28. Revenue of $15M beats by $12M. Shares +2.4%. Press Release For further details see: Milestone Pharmaceuticals EPS beats by $0.28, beats on revenue